• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis

by | Mar 14, 2025 | Publications

Blood Cancer J. 2025 Mar 13;15(1):37. doi: 10.1038/s41408-025-01253-5. ABSTRACT The treatment landscape for transplant-eligible patients with newly diagnosed multiple myeloma (TE-NDMM) has evolved with the introduction of daratumumab-based quadruplet regimens. Adding...

Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review

by | Mar 8, 2025 | Publications

Cancer Med. 2025 Mar;14(5):e70585. doi: 10.1002/cam4.70585. ABSTRACT BACKGROUND: There is a lack of clear guidance on the appropriate next choice of therapy for patients with relapsed/refractory multiple myeloma who become refractory to daratumumab, an anti-CD38...

Evaluation of anti-CD38 monoclonal antibody-based immunotherapy in multiple myeloma with renal insufficiency: a systematic review and meta-analysis

by | Feb 18, 2025 | Publications

Ther Adv Hematol. 2025 Feb 17;16:20406207251319593. doi: 10.1177/20406207251319593. eCollection 2025. ABSTRACT BACKGROUND: Renal impairment is one of the common characteristics of multiple myeloma (MM) and makes management of MM more complicated. Even though...

Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis

by | Feb 7, 2025 | Publications

Hematology. 2025 Dec;30(1):2462249. doi: 10.1080/16078454.2025.2462249. Epub 2025 Feb 6. ABSTRACT BACKGROUND: The current study aimed to compare treatment responses, the incidence of the need for auto-HSCT, and the occurrence of specific adverse events (AEs) between...

Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia

by | Feb 5, 2025 | Publications

Front Oncol. 2025 Jan 21;14:1535869. doi: 10.3389/fonc.2024.1535869. eCollection 2024. ABSTRACT BACKGROUND: Regulatory bodies have recently approved chimeric antigen receptor (CAR)-T cell therapies for patients with multiple myeloma (MM), but the treatment process...

A Systematic Review and Meta-analysis on the Safety and Efficacy of CAR T Cell Therapy Targeting GPRC5D in Patients with Multiple Myeloma: A New Insight in Cancer Immunotherapy

by | Feb 4, 2025 | Publications

Anticancer Agents Med Chem. 2025 Jan 30. doi: 10.2174/0118715206350342241224073809. Online ahead of print. ABSTRACT BACKGROUND: Despite ongoing advances and introducing innovative therapeutic approaches for the treatment of multiple myeloma (MM), relapses are common,...
« Older Entries
Next Entries »

Recent Content

  • LY6E as a new prognostic biomarker of multiple myeloma-related bone disease
  • Dynamic monitoring of M-protein quantification by immunotyping using capillary zone electrophoresis during the chemotherapy of patients with multiple myeloma
  • Efficacy and Safety of Quadruplet Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma: A Systematic Review and Meta-Analysis
  • Nivolumab May Restore T-Cell Fitness Following CAR T-Cell Therapy in Patients With Multiple Myeloma
  • Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study
  • Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma
  • Prognostic and clinicopathological value of the controlling nutritional status score in patients with multiple myeloma: a meta-analysis
  • What Role Does MRD Play in Multiple Myeloma Treatment Decision Making?
  • Depression, anxiety prevalent among adults with lymphoma, multiple myeloma
  • Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT